TSXV - Delayed Quote CAD

DIAGNOS Inc. (ADK.V)

0.2000

+0.0150

+(8.11%)

At close: June 13 at 3:59:59 PM EDT

DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States

BROSSARD, Quebec, June 10, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Mr. Ed Weiner has joined the Corporation’s Advisory Board. Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to pro

GlobeNewswire 4 days ago

DGNOF
DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market

BROSSARD, Quebec, June 04, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is thrilled to announce that Dr. Tomas J. Philipson has joined the Corporation’s Advisory Board. Dr. Tomas J. Philipson is considered an expert in US economic policy, particularly health care policy and appears often on major media outle

GlobeNewswire 10 days ago

DGNOF
DIAGNOS Announces the Engagement of Allele Capital Partners

BROSSARD, Quebec, May 23, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Allele Capital Partners, LLC (“Allele”) to provide capital markets advisory and social media services to the Corporation. As per the agreement signed between Allele and DIAGNOS, Allele is entitled to a monthly

GlobeNewswire 22 days ago

DGNOF
DIAGNOS Announces Amendment to Convertible Debentures

BROSSARD, Quebec, May 20, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the maturity date for $300,000 unsecured convertible debentures (each a “Debenture”) issued as part of a private placement of units initially announced on May 18, 2023. The maturity date, initially set

GlobeNewswire 25 days ago

DGNOF
DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application

BROSSARD, Quebec, April 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application. As part of its ongoing ISO 27001 certification process, DIAGNOS is pleased to announce that

GlobeNewswire last month

DGNOF
DIAGNOS Provides Additional Information on Amendment to Convertible Debentures

BROSSARD, Quebec, April 14, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), wishes to provide additional information to the February 28, 2025 announcement on amendment to convertible debentures. One insider of the Corporation, Mr. André Larente, is the beneficial owner of 2 convertible debentures bein

GlobeNewswire last month

DGNOF
DIAGNOS Provides Update on its Health Canada Medical Device Licence Application

BROSSARD, Quebec, April 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), provides an update on the progress of its Medical device license application for CARA System, submitted to Health Canada in early September 2024. Following the submission of its application in early September, DIAGNOS has enga

GlobeNewswire 2 months ago

DGNOF
DIAGNOS Opens First US Office in Florida

BROSSARD, Quebec, March 31, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of certain ophthalmic health issues using advanced technology based on Artificial Intelligence (AI), is excited to announce the opening of a new office in Fort Lauderdale that will serve to meet potential clients and conduct demos to key stakeholders in the ophthalmic and optometry sectors in Florida. As part of its growth st

GlobeNewswire 2 months ago

DGNOF
DIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical Device

BROSSARD, Quebec, March 12, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it is officially filing for Saudi Food and Drug Administration (Saudi FDA) authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory proces

GlobeNewswire 3 months ago

DGNOF
DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist

BROSSARD, Quebec, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it is officially filing for U.S. Food and Drug Administration (FDA) pre-market authorization of its CARA SYSTEM, a machine-learning-enabled medical device (MLMD). To ensure a smooth regulatory pro

GlobeNewswire 3 months ago

DGNOF
DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference

Brossard, Quebec--(Newsfile Corp. - February 24, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 8th Annual Conference in Toronto, Canada March 6th 2025.This private event brings together the largest Canadian base of investors looking ...

Newsfile 3 months ago

DGNOF
Correction - Diagnos Announces Closing of Private Placement

In the original press release dated February 5, 2025, announcing the closing of a private placement of 6,715,370 units issued at a price of $0.30 per unit, for gross proceeds of $2,014,611, the number of units, the amount of gross proceeds and the amount of cash remuneration to finders were incorrect. The corrected news release is presented below. BROSSARD, Quebec, Feb. 14, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in earl

GlobeNewswire 3 months ago

DGNOF
DIAGNOS Announces Closing of Private Placement

BROSSARD, Quebec, Feb. 05, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing, today, of a non-brokered private placement of 6,715,370 units (each a “Unit”) issued at a price of $0.30 per Unit, for gross proceeds of $2,014,611 (“Private Placement”). Each Unit consists of: One (1) common share (“Share”), a

GlobeNewswire 4 months ago

DGNOF
DIAGNOS Announces Financial Contribution of $400,000 from the Government of Canada

BROSSARD, Quebec, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that it was granted a financial contribution of up to CA$400,000 from the Canada Economic Development for Quebec Regions organization (CED) to implement an international marketing strategy for CARA (the “Proj

GlobeNewswire 4 months ago

DGNOF
DIAGNOS to Present at The Microcap Conference 2025

BROSSARD, Quebec, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in

GlobeNewswire 4 months ago

DGNOF
DIAGNOS Announces the Engagement of Promoter

BROSSARD, Quebec, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the engagement of Outside The Box Capital Inc. (“OTB”) to provide marketing and promotional services to the Corporation. As per the agreement signed between OTB and DIAGNOS, OTB is entitled to a compensation

GlobeNewswire 4 months ago

DGNOF
DIAGNOS Second Quarter 2025 Earnings: Revenues Disappoint

DIAGNOS ( CVE:ADK ) Second Quarter 2025 Results Key Financial Results Net loss: CA$1.02m (loss widened by 36% from 2Q...

Simply Wall St. 6 months ago

DGNOF
DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange

BROSSARD, Quebec, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A) a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the cross-listing of the Corporation's subordinate common shares on the Frankfurt Stock Exchange ("FWB") under the trading symbol "4D4A". FWB is the largest of Germany’s seven stock exchanges. It facili

GlobeNewswire 6 months ago

DGNOF
DIAGNOS Announces the Engagement of Market Maker Consultant

BROSSARD, Quebec, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the engagement of Red Cloud Securities Inc. (“Red Cloud”) to provide market making services to the Corporation. As per the agreement signed between Red Cloud and DIAGNOS, Red Cloud is entitled to a monthly flat fee of

GlobeNewswire 7 months ago

DGNOF
DIAGNOS Announces Grant of Stock Options

BROSSARD, Quebec, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces a grant of an aggregate number of 1,550,000 stock options to its directors and officers. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The date of the grant is October 3, 2024. The exercise price of

GlobeNewswire 8 months ago

DGNOF

Performance Overview

Return	ADK.V	S&P/TSX Composite index (^GSPTSE)
YTD	-33.33%	+7.65%
1-Year	-37.50%	+22.15%
3-Year	+42.86%	+34.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

DIAGNOS Inc. (ADK.V)

DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States

DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market

DIAGNOS Announces the Engagement of Allele Capital Partners

DIAGNOS Announces Amendment to Convertible Debentures

DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application

DIAGNOS Provides Additional Information on Amendment to Convertible Debentures

DIAGNOS Provides Update on its Health Canada Medical Device Licence Application

DIAGNOS Opens First US Office in Florida

DIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical Device

DIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory Specialist

DIAGNOS to Present at Centurion One Capital 8th Annual Toronto Growth Conference

Correction - Diagnos Announces Closing of Private Placement

DIAGNOS Announces Closing of Private Placement

DIAGNOS Announces Financial Contribution of $400,000 from the Government of Canada

DIAGNOS to Present at The Microcap Conference 2025

DIAGNOS Announces the Engagement of Promoter

DIAGNOS Second Quarter 2025 Earnings: Revenues Disappoint

DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange

DIAGNOS Announces the Engagement of Market Maker Consultant

DIAGNOS Announces Grant of Stock Options

Performance Overview